{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:43:34Z","timestamp":1789746214125,"version":"4.0.1"},"reference-count":159,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201788"],"award-info":[{"award-number":["81201788"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e25747","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T12:36:43Z","timestamp":1707482203000},"page":"e25747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immune checkpoint inhibitor-associated cardiovascular toxicities: A review"],"prefix":"10.1016","volume":"10","author":[{"given":"Guihong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-6342","authenticated-orcid":false,"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huashan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e25747_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib2","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1042\/CS20200331","article-title":"Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"135","author":"Baik","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.heliyon.2024.e25747_bib4","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib6","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D'Souza","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib17","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25747_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41572-020-0179-8","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Manuel Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.heliyon.2024.e25747_bib19","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.heliyon.2024.e25747_bib20","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e25747_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib22","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib23","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.heliyon.2024.e25747_bib24","article-title":"Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"11","author":"Hu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e25747_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-pharmtox-010919-023451","article-title":"Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure","volume":"61","author":"Waliany","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaccao.2019.08.012","article-title":"Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor","volume":"1","author":"Waliany","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2017.06.2452","article-title":"Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody correlated with increased T-cell infiltration into cardiac and lung tissues","volume":"99","author":"Myers","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.heliyon.2024.e25747_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.111045","article-title":"Chemoprotective role of an extract of the heart of the Phoenix dactylifera tree on adriamycin-induced cardiotoxicity and nephrotoxicity by regulating apoptosis, oxidative stress and PD-1 suppression","volume":"135","author":"Sahyon","year":"2020","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib31","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.heliyon.2024.e25747_bib33","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/annonc\/mdx326","article-title":"Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody","volume":"28","author":"Tomita","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib34","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy- ASCO guideline Update.pdf","volume":"39","author":"Bryan","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.heliyon.2024.e25747_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.immunol.18.1.309","article-title":"Ashwell FWML, Vacchio aMS: glucocorticoids in T cell development and function","volume":"18","author":"Jonathan","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib36","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib37","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","article-title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","volume":"31","author":"Doms","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib38","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib39","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor\u2013associated Myocarditis.pdf","volume":"380","author":"Joe-Elie Salem","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e25747_bib40","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.3390\/cancers14215403","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: what a cardio-oncology team should know and do","volume":"14","author":"Zito","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.heliyon.2024.e25747_bib41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e25747_bib42","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.it.2013.07.003","article-title":"B7 family checkpoint regulators in immune regulation and disease","volume":"34","author":"Ceeraz","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25747_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12943-021-01486-5","article-title":"Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy","volume":"21","author":"Lian","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.heliyon.2024.e25747_bib48","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.it.2017.04.002","article-title":"Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo","volume":"38","author":"Halle","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.immuni.2018.03.009","article-title":"Unconventional T cell targets for cancer immunotherapy","volume":"48","author":"Godfrey","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e25747_bib50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib51","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-020-0296-3","article-title":"Modulation of regulatory T cell function and stability by co-inhibitory receptors","volume":"20","author":"Lucca","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 8","key":"10.1016\/j.heliyon.2024.e25747_bib52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/annonc\/mds256","article-title":"Immuno-oncology: understanding the function and dysfunction of the immune system in cancer","volume":"23","author":"Finn","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib53","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cvr\/cvz025","article-title":"T cell checkpoint regulators in the heart","volume":"115","author":"Grabie","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib54","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.celrep.2017.02.079","article-title":"Myocardial infarction primes autoreactive T cells through activation of dendritic cells","volume":"18","author":"Van der Borght","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/j.heliyon.2024.e25747_bib55","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib56","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Stephen Hodi Md","year":"2010","journal-title":"The new england journal of medicine"},{"key":"10.1016\/j.heliyon.2024.e25747_bib57","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits 11.+-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib58","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e25747_bib60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25747_bib61","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/s41467-022-29286-5","article-title":"The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity","volume":"13","author":"Maurer","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.heliyon.2024.e25747_bib62","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib63","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib64","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib65","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25747_bib67","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.heliyon.2024.e25747_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","article-title":"Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy","volume":"86","author":"Gaikwad","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25747_bib69","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib71","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e25747_bib72","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"issue":"6307","key":"10.1016\/j.heliyon.2024.e25747_bib73","doi-asserted-by":"crossref","first-page":"aah3374","DOI":"10.1126\/science.aah3374","article-title":"Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e25747_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179958","article-title":"LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors","volume":"23","author":"Sauer","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.heliyon.2024.e25747_bib75","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib76","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25747_bib77","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"WorkmanCJ","year":"2004","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25747_bib78","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.heliyon.2024.e25747_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102310","article-title":"Balancing cancer immunotherapy and immune-related adverse events: the emerging role of regulatory T cells","volume":"104","author":"Alissafi","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.heliyon.2024.e25747_bib80","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41577-018-0065-8","article-title":"Cardioimmunology: the immune system in cardiac homeostasis and disease","volume":"18","author":"Swirski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib81","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1093\/eurheartj\/ehz516","article-title":"Pathologic T-cell response in ischaemic failing hearts elucidated by T-cell receptor sequencing and phenotypic characterization","volume":"40","author":"Tang","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib82","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1111\/bph.13613","article-title":"T-cell immunity in myocardial inflammation: pathogenic role and therapeutic manipulation","volume":"174","author":"Stephenson","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25747_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0167-5273(96)02588-0","article-title":"The role of sensitized T-cells in myocarditis and dilated cardiomyopathy","volume":"54","author":"Schwimmbeck Cb","year":"1996","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib84","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1152\/physrev.00068.2017","article-title":"Macrophages and cardiovascular Health","volume":"98","author":"Frodermann","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.heliyon.2024.e25747_bib85","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib86","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25747_bib87","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1736792","article-title":"LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma\/T cell co-cultures","volume":"9","author":"Gestermann","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.heliyon.2024.e25747_bib88","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","article-title":"PD-1 and LAG-3 dominate checkpoint receptor-mediated T-cell inhibition in renal cell carcinoma","volume":"7","author":"Zelba","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib89","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41401-018-0062-2","article-title":"Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.heliyon.2024.e25747_bib90","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.heliyon.2024.e25747_bib91","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor\u2013related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.heliyon.2024.e25747_bib92","first-page":"131","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.heliyon.2024.e25747_bib93","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib94","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib95","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.heliyon.2024.e25747_bib97","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e25747_bib98","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cvr\/cvr063","article-title":"Comparison of IL-10 and MCP-1-7ND gene transfer with AAV9 vectors for protection from murine autoimmune myocarditis","volume":"91","author":"Kaya","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib99","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e25747_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100216","article-title":"Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy","volume":"6","author":"Delombaerde","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.heliyon.2024.e25747_bib101","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e25747_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002007","article-title":"Electrocardiographic features of immune checkpoint inhibitor associated myocarditis","volume":"9","author":"Zlotoff","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e25747_bib103","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/eurheartj\/ehaa601","volume":"42","author":"Barbato","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib104","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib105","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib106","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"Cardiovascular magnetic resonance in myocarditis: a JACC White Paper","volume":"53","author":"Friedrich","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib107","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib108","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune checkpoint inhibitor-associated pericarditis","volume":"14","author":"Altan","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib109","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.117.030834","article-title":"Left ventricular biopsy in the diagnosis of myocardial diseases","volume":"137","author":"Frey","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e25747_bib110","first-page":"1714","article-title":"National comprehensive cancer network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer Jrl","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib111","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e25747_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e25747_bib113","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib114","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib115","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib116","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11864-021-00845-0","article-title":"Circulating biomarkers for cardiotoxicity risk prediction","volume":"22","author":"Gong","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib117","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e25747_bib118","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(04)15648-1","volume":"363","author":"Troughton","year":"2004","journal-title":"Pericarditis. Lancet"},{"key":"10.1016\/j.heliyon.2024.e25747_bib119","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib120","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jacc.2020.08.003","article-title":"Effect of anti-inflammatory drugs on clinical outcomes in patients with malignant pericardial effusion","volume":"76","author":"Kim","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib121","first-page":"3553","article-title":"Immune checkpoint inhibitors myocarditis: not all cases are clinically patent","volume":"39","author":"Thibault","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib122","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrcardio.2016.108","article-title":"Psychosocial and psychoneuroendocrinal aspects of Takotsubo syndrome","volume":"13","author":"Kastaun","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib123","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ejhf.424","article-title":"Current state of knowledge on Takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the heart failure association of the European society of cardiology","volume":"18","author":"Lyon","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.heliyon.2024.e25747_bib124","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1136\/heartjnl-2016-309783","article-title":"Takotsubo syndrome: aetiology, presentation and treatment","volume":"103","author":"Kato","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.heliyon.2024.e25747_bib125","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ejechocard\/jer059","article-title":"Echocardiographic assessment of regional left ventricular wall motion abnormalities in patients with tako-tsubo cardiomyopathy: comparison with anterior myocardial infarction","volume":"12","author":"Citro","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.heliyon.2024.e25747_bib126","first-page":"1187","article-title":"Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Ederhy","year":"2018","journal-title":"JACC: Cardiovascular Imaging"},{"key":"10.1016\/j.heliyon.2024.e25747_bib127","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/eurheartj\/ehy077","article-title":"International expert consensus document on Takotsubo syndrome (Part II): diagnostic workup, outcome, and management","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib128","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.heliyon.2024.e25747_bib130","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12265-019-09924-y","article-title":"Electrophysiology translational considerations in cardio-oncology: QT and beyond","volume":"13","author":"Alomar","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e25747_bib131","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: a scientific statement from the American heart association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e25747_bib132","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cmpb.2015.12.024","article-title":"Arrhythmia recognition and classification using combined linear and nonlinear features of ECG signals","volume":"127","author":"Elhaj","year":"2016","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.heliyon.2024.e25747_bib133","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib134","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/BOR.0000000000000672","article-title":"Immune checkpoint inhibitors and vasculitis","volume":"32","author":"Boland","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib136","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib137","first-page":"24","article-title":"Association between loss of immune checkpoint programmed cell death protein 1 and active ANCA-associated renal vasculitis","author":"Hakroush","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.heliyon.2024.e25747_bib138","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.jaccas.2020.07.028","article-title":"Myocardial vasculitis associated with the immune checkpoint inhibitor pembrolizumab","volume":"2","author":"Oishi","year":"2020","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.heliyon.2024.e25747_bib139","doi-asserted-by":"crossref","first-page":"H1052","DOI":"10.1152\/ajpheart.00024.2017","article-title":"Immune checkpoint dysfunction in large and medium vessel vasculitis","volume":"312","author":"Watanabe","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib140","doi-asserted-by":"crossref","first-page":"l1964","DOI":"10.1136\/bmj.l1964","article-title":"Giant cell arteritis","volume":"365","author":"Lazarewicz","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e25747_bib141","doi-asserted-by":"crossref","first-page":"ITC65","DOI":"10.7326\/AITC201611010","article-title":"Giant cell arteritis","volume":"165","author":"Hoffman","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib142","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/CIRCULATIONAHA.120.046657","article-title":"Medium- and large-vessel vasculitis","volume":"143","author":"Saadoun","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e25747_bib143","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-019-0828-7","article-title":"Systemic vasculitis associated with immune check point inhibition: analysis and review","volume":"21","author":"Crout","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.heliyon.2024.e25747_bib144","first-page":"476","article-title":"Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event","volume":"36","author":"Cautela","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib145","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e25747_bib146","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib147","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cvr\/cvx248","article-title":"Exploring immune checkpoints as potential therapeutic targets in atherosclerosis","volume":"114","author":"Kusters","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib148","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.5114\/amsad.2017.72531","article-title":"A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab","volume":"2","author":"Nykl","year":"2017","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"10.1016\/j.heliyon.2024.e25747_bib149","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2013.06.014","article-title":"Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells","volume":"230","author":"Dietel","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.heliyon.2024.e25747_bib151","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib152","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib153","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.heliyon.2024.e25747_bib154","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.heliyon.2024.e25747_bib155","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cpt.2615","article-title":"Immune checkpoint inhibitors and venous thromboembolism: an analysis of the WHO pharmacovigilance database","volume":"112","author":"Allouchery","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.heliyon.2024.e25747_bib156","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz265.021","article-title":"Incidence of vascular thromboembolism events in cancer patients receiving immunotherapy: a single institution experience","volume":"30","author":"Guti\u00e9rrez Sainz","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.heliyon.2024.e25747_bib157","first-page":"9","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25747_bib158","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"etc.: incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.pdf","volume":"137","author":"Florian Moik","year":"2021","journal-title":"blood"},{"key":"10.1016\/j.heliyon.2024.e25747_bib159","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.heliyon.2024.e25747_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102280","article-title":"Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: a systematic review and meta-analysis","volume":"100","author":"Giustozzi","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.heliyon.2024.e25747_bib161","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2021.10.014","article-title":"Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy","volume":"208","author":"Hill","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.heliyon.2024.e25747_bib162","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib163","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","article-title":"Platelets at the interface of thrombosis, inflammation, and cancer","volume":"126","author":"Franco","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e25747_bib164","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/eji.201847645","article-title":"Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient","volume":"48","author":"Horio","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060762","article-title":"Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies","volume":"8","author":"Sato","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib166","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrclinonc.2012.106","article-title":"Thrombosis and cancer","volume":"9","author":"Young","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.heliyon.2024.e25747_bib167","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/jth.15883","article-title":"The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: a Danish cohort study","volume":"20","author":"Overvad","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.heliyon.2024.e25747_bib168","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.heliyon.2024.e25747_bib169","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402401778X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402401778X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:51:47Z","timestamp":1769046707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402401778X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":159,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S240584402401778X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25747","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-associated cardiovascular toxicities: A review","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e25747"}}